<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Ophthalmol</journal-id><journal-id journal-id-type="iso-abbrev">Clin Ophthalmol</journal-id><journal-id journal-id-type="publisher-id">Clinical Ophthalmology</journal-id><journal-title-group><journal-title>Clinical Ophthalmology (Auckland, N.Z.)</journal-title></journal-title-group><issn pub-type="ppub">1177-5467</issn><issn pub-type="epub">1177-5483</issn><publisher><publisher-name>Dove Medical Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29398903</article-id><article-id pub-id-type="pmc">5775735</article-id><article-id pub-id-type="doi">10.2147/OPTH.S150433</article-id><article-id pub-id-type="publisher-id">opth-12-161</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Comparison of a single-dose vectored thermal pulsation procedure with a 3-month course of daily oral doxycycline for moderate-to-severe meibomian gland dysfunction</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Hagen</surname><given-names>Kerry B</given-names></name><xref ref-type="aff" rid="af1-opth-12-161">1</xref></contrib><contrib contrib-type="author"><name><surname>Bedi</surname><given-names>Raman</given-names></name><xref ref-type="aff" rid="af2-opth-12-161">2</xref></contrib><contrib contrib-type="author"><name><surname>Blackie</surname><given-names>Caroline A</given-names></name><xref ref-type="aff" rid="af3-opth-12-161">3</xref><xref ref-type="corresp" rid="c1-opth-12-161"></xref></contrib><contrib contrib-type="author"><name><surname>Christenson-Akagi</surname><given-names>Kellie J</given-names></name><xref ref-type="aff" rid="af1-opth-12-161">1</xref></contrib></contrib-group><aff id="af1-opth-12-161">
<label>1</label>EyeHealth Northwest, Portland, OR, USA</aff><aff id="af2-opth-12-161">
<label>2</label>Iris Advanced Eye Centre, Chandigarh, India</aff><aff id="af3-opth-12-161">
<label>3</label>TearScience, Inc., Morrisville, NC, USA</aff><author-notes><corresp id="c1-opth-12-161">Correspondence: Caroline A Blackie, TearScience, Inc., 5151 McCrimmon Parkway, Suite 250, Morrisville, NC 27560, USA, Email <email>cblackie@its.jnj.com</email></corresp></author-notes><pub-date pub-type="collection"><year>2018</year></pub-date><pub-date pub-type="epub"><day>17</day><month>1</month><year>2018</year></pub-date><volume>12</volume><fpage>161</fpage><lpage>168</lpage><permissions><copyright-statement>© 2018 Hagen et al. This work is published and licensed by Dove Medical Press Limited</copyright-statement><copyright-year>2018</copyright-year><license><license-p>The full terms of this license are available at <ext-link ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link> and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.</license-p></license></permissions><abstract><sec><title><offsets xml_i="3550" xml_f="3557" txt_i="11" txt_f="18">Purpose</offsets></title><p><offsets xml_i="3568" xml_f="3793" txt_i="19" txt_f="244">The aim of this study was to compare the efficacy of a single bilateral 12-minute vectored thermal pulsation (VTP) procedure versus daily oral doxycycline for 3 months for moderate-to-severe meibomian gland dysfunction (MGD).</offsets></p></sec><sec><title><offsets xml_i="3815" xml_f="3822" txt_i="246" txt_f="253">Methods</offsets></title><p><offsets xml_i="3833" xml_f="4379" txt_i="254" txt_f="800">This prospective, randomized, parallel-group, single-masked study included 28 subjects who received either a single-dose VTP or 3 months of doxycycline treatment. At baseline and 3 months post treatment, all subjects were evaluated for the following: dry eye symptoms with a standard dry eye questionnaire (the Standard Patient Evaluation for Eye Dryness [SPEED]), meibomian gland (MG) function by counting the number of glands yielding liquid secretion with the MG evaluator (MGE), tear breakup time (TBUT) and corneal and conjunctival staining.</offsets></p></sec><sec><title><offsets xml_i="4401" xml_f="4408" txt_i="802" txt_f="809">Results</offsets></title><p><offsets xml_i="4419" xml_f="5019" txt_i="810" txt_f="1410">In the VTP group, at 3 months, there was a significant improvement in MG function (4.00±1.47 to 7.73±5.53), SPEED score (11.00±3.30 to 5.42±2.15), TBUT (6.26±2.01 to 8.44±1.81), corneal staining (0.38±0.50 to 0.12±0.33) and conjunctival staining (1.69±1.93 to 0.62±0.85). In the doxycycline group, there was a significant improvement in MG function (4.63±1.41 to 10.63±5.91), SPEED score (13.42±4.17 to 9.42±5.47) and conjunctival staining (2.38±1.88 to 1.13±1.51), but the improvement in TBUT (6.90±2.56 to 7.59±2.03) and corneal staining (0.21±0.41 to 0.13±0.34) was not statistically significant (</offsets><italic><offsets xml_i="5027" xml_f="5028" txt_i="1410" txt_f="1411">p</offsets></italic><offsets xml_i="5037" xml_f="5048" txt_i="1411" txt_f="1422">=0.262 and </offsets><italic><offsets xml_i="5056" xml_f="5057" txt_i="1422" txt_f="1423">p</offsets></italic><offsets xml_i="5066" xml_f="5157" txt_i="1423" txt_f="1514">=0.414, respectively). At 3 months, SPEED score was significantly better in the VTP group (</offsets><italic><offsets xml_i="5165" xml_f="5166" txt_i="1514" txt_f="1515">p</offsets></italic><offsets xml_i="5175" xml_f="5242" txt_i="1515" txt_f="1579">&lt;0.05); other parameters were comparable between the two groups.</offsets></p></sec><sec><title><offsets xml_i="5264" xml_f="5274" txt_i="1581" txt_f="1591">Conclusion</offsets></title><p><offsets xml_i="5285" xml_f="5782" txt_i="1592" txt_f="2089">A single 12-minute bilateral VTP procedure was significantly more effective than the 3-month daily course of oral doxycycline at improving the dry eye symptoms secondary to MGD. A single 12-minute VTP treatment was at least as effective as a dose of doxycycline for 3 months, in improving MG function and all measured signs of MGD. Given the minimal risk profile of the single VTP procedure over long-term doxycycline use, a single VTP presents a favorable alternative to long-term antibiotic use.</offsets></p></sec></abstract><kwd-group><title>Keywords</title><kwd>meibomian gland dysfunction</kwd><kwd>dry eye</kwd><kwd>vectored thermal pulsation</kwd><kwd>LipiFlow</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title><offsets xml_i="6019" xml_f="6031" txt_i="2098" txt_f="2110">Introduction</offsets></title><p><offsets xml_i="6042" xml_f="6137" txt_i="2111" txt_f="2206">Meibomian gland dysfunction (MGD) has recently been recognized as the leading cause of dry eye.</offsets><xref rid="b1-opth-12-161" ref-type="bibr"><offsets xml_i="6180" xml_f="6181" txt_i="2206" txt_f="2207">1</offsets></xref><offsets xml_i="6188" xml_f="6518" txt_i="2207" txt_f="2537"> MGD is a highly prevalent, chronic and progressive condition that can be diagnosed by observable compromise to the function and/or structure of the meibomian glands (MGs). Later stage disease can present with additional findings including ocular surface inflammation, changes to the tear film and lid margin and dry eye symptoms.</offsets><xref rid="b1-opth-12-161" ref-type="bibr"><offsets xml_i="6561" xml_f="6562" txt_i="2537" txt_f="2538">1</offsets></xref><offsets xml_i="6569" xml_f="6570" txt_i="2538" txt_f="2539">,</offsets><xref rid="b2-opth-12-161" ref-type="bibr"><offsets xml_i="6613" xml_f="6614" txt_i="2539" txt_f="2540">2</offsets></xref></p><p><offsets xml_i="6628" xml_f="6907" txt_i="2541" txt_f="2820">While there are many adjunctive treatments available for the ongoing management of MGD, eg, daily heat and massage of the external lid surface, successful long-term rehabilitation of MG function usually requires that gland obstruction be treated by evacuating the gland contents.</offsets><xref rid="b3-opth-12-161" ref-type="bibr"><offsets xml_i="6950" xml_f="6951" txt_i="2820" txt_f="2821">3</offsets></xref><offsets xml_i="6958" xml_f="7013" txt_i="2821" txt_f="2876"> Vectored thermal pulsation (VTP), described elsewhere,</offsets><xref rid="b4-opth-12-161" ref-type="bibr"><offsets xml_i="7056" xml_f="7057" txt_i="2876" txt_f="2877">4</offsets></xref><offsets xml_i="7064" xml_f="7237" txt_i="2877" txt_f="3050"> is specifically designed and has been shown to be highly effective at evacuating the contents of the MGs of all four eyelids simultaneously in a single 12-minute treatment.</offsets><xref rid="b3-opth-12-161" ref-type="bibr"><offsets xml_i="7280" xml_f="7281" txt_i="3050" txt_f="3051">3</offsets></xref><offsets xml_i="7288" xml_f="7492" txt_i="3051" txt_f="3255"> The successful use of VTP has been shown in multiple patient cohorts with MGD, including those with dry eye, refractory dry eye, refractory dry eye post LASIK, Sjögren’s disease and contact lens wearers.</offsets><xref rid="b5-opth-12-161" ref-type="bibr"><offsets xml_i="7535" xml_f="7536" txt_i="3255" txt_f="3256">5</offsets></xref><offsets xml_i="7543" xml_f="7544" txt_i="3256" txt_f="3257">–</offsets><xref rid="b8-opth-12-161" ref-type="bibr"><offsets xml_i="7587" xml_f="7588" txt_i="3257" txt_f="3258">8</offsets></xref><offsets xml_i="7595" xml_f="7747" txt_i="3258" txt_f="3410"> Previous clinical studies have shown sustained improvement in MG function and dry eye symptoms with a single 12-minute VTP procedure over 12–36 months.</offsets><xref rid="b5-opth-12-161" ref-type="bibr"><offsets xml_i="7790" xml_f="7791" txt_i="3410" txt_f="3411">5</offsets></xref><offsets xml_i="7798" xml_f="7799" txt_i="3411" txt_f="3412">,</offsets><xref rid="b9-opth-12-161" ref-type="bibr"><offsets xml_i="7842" xml_f="7843" txt_i="3412" txt_f="3413">9</offsets></xref></p><p><offsets xml_i="7857" xml_f="8268" txt_i="3414" txt_f="3825">Despite the awareness that obstruction is the core mechanism in almost all MGD, the field lacks consensus on generalized treatment recommendations for the evacuation of gland contents for MGD. In the cases of more advanced MG disease, inflammation of the eyelid tissue may also require treatment. Similarly, there is little consensus as to how to manage inflammation of the eyelid tissue in later-stage disease.</offsets><xref rid="b10-opth-12-161" ref-type="bibr"><offsets xml_i="8312" xml_f="8314" txt_i="3825" txt_f="3827">10</offsets></xref><offsets xml_i="8321" xml_f="8495" txt_i="3827" txt_f="4001"> Antibiotic agents, including macrolides, and tetracycline and its derivatives have been shown to be beneficial for the management of various chronic inflammatory conditions,</offsets><xref rid="b11-opth-12-161" ref-type="bibr"><offsets xml_i="8539" xml_f="8541" txt_i="4001" txt_f="4003">11</offsets></xref><offsets xml_i="8548" xml_f="8673" txt_i="4003" txt_f="4128"> and doxycycline is a long-acting analog of tetracycline that has been effectively used for the treatment of dry eye disease.</offsets><xref rid="b12-opth-12-161" ref-type="bibr"><offsets xml_i="8717" xml_f="8719" txt_i="4128" txt_f="4130">12</offsets></xref><offsets xml_i="8726" xml_f="8727" txt_i="4130" txt_f="4131">–</offsets><xref rid="b16-opth-12-161" ref-type="bibr"><offsets xml_i="8771" xml_f="8773" txt_i="4131" txt_f="4133">16</offsets></xref><offsets xml_i="8780" xml_f="9086" txt_i="4133" txt_f="4439"> Its therapeutic efficacy has been attributed to various factors including its ability to inhibit the synthesis or activation of proinflammatory mediators in the corneal epithelium and its antimicrobial and antichemotactic properties, which leads to improvement in dry eye symptoms and tear film stability.</offsets><xref rid="b12-opth-12-161" ref-type="bibr"><offsets xml_i="9130" xml_f="9132" txt_i="4439" txt_f="4441">12</offsets></xref><offsets xml_i="9139" xml_f="9140" txt_i="4441" txt_f="4442">,</offsets><xref rid="b14-opth-12-161" ref-type="bibr"><offsets xml_i="9184" xml_f="9186" txt_i="4442" txt_f="4444">14</offsets></xref><offsets xml_i="9193" xml_f="9283" txt_i="4444" txt_f="4534"> However, long-term use of doxycycline can be problematic due to the risk of side effects.</offsets><xref rid="b14-opth-12-161" ref-type="bibr"><offsets xml_i="9327" xml_f="9329" txt_i="4534" txt_f="4536">14</offsets></xref><offsets xml_i="9336" xml_f="9337" txt_i="4536" txt_f="4537">,</offsets><xref rid="b15-opth-12-161" ref-type="bibr"><offsets xml_i="9381" xml_f="9383" txt_i="4537" txt_f="4539">15</offsets></xref></p><p><offsets xml_i="9397" xml_f="9581" txt_i="4540" txt_f="4724">Analysis of biochemical properties of meibomian secretions following oral doxycycline treatment has shown improvement in the composition and characteristics of the MG secretions (MGS).</offsets><xref rid="b12-opth-12-161" ref-type="bibr"><offsets xml_i="9625" xml_f="9627" txt_i="4724" txt_f="4726">12</offsets></xref><offsets xml_i="9634" xml_f="9912" txt_i="4726" txt_f="5004"> These changes in the properties of meibum appear to improve its fluidity and enhance gland function. The purpose of the current study was to compare the effect of a 3-month course of daily oral doxycycline therapy and a single 12-minute VTP procedure on moderate-to-severe MGD.</offsets></p></sec><sec sec-type="methods"><title><offsets xml_i="9953" xml_f="9960" txt_i="5006" txt_f="5013">Methods</offsets></title><p><offsets xml_i="9971" xml_f="10278" txt_i="5014" txt_f="5321">This prospective, randomized, parallel-group, single-masked study was conducted in compliance with the tenets of Declaration of Helsinki. The study was approved by Sterling Institutional Review Board (Atlanta, GA, USA). All study participants were fully consented, and written informed consent was obtained.</offsets></p><sec sec-type="methods"><title><offsets xml_i="10313" xml_f="10325" txt_i="5322" txt_f="5334">Study design</offsets></title><p><offsets xml_i="10336" xml_f="11197" txt_i="5335" txt_f="6196">This study included 28 subjects with moderate-to-severe MGD, who were randomized to receive either doxycycline treatment or VTP procedure in 1:1 ratio (14 patients in the doxycycline group and 14 in the VTP group). The subjects randomized to the doxycycline group were administered daily oral doxycycline for 3 months (100 mg twice daily [BID] for the first 14 days and 100 mg once daily for days 15–90) and those randomized to the VTP group received a single bilateral 12-minute VTP procedure with LipiFlow System (TearScience, Inc., Morrisville, NC, USA). The single examiner (KBH) was masked to the treatment type assigned to each subject. To ensure masking of the examiner, subjects randomized to VTP procedure were treated by another practitioner and subjects were instructed to not comment on their treatment type to the examiner at the final examination.</offsets></p></sec><sec><title><offsets xml_i="11219" xml_f="11237" txt_i="6198" txt_f="6216">Inclusion criteria</offsets></title><p><offsets xml_i="11248" xml_f="11558" txt_i="6217" txt_f="6527">Subjects eligible for participating in the study met the following inclusion criteria: aged 21 years or older; provided written informed consent and were willing to comply with the study procedures and follow-up schedule; a Standard Patient Evaluation for Eye Dryness (SPEED) score of ≥6 at the baseline visit;</offsets><xref rid="b17-opth-12-161" ref-type="bibr"><offsets xml_i="11602" xml_f="11604" txt_i="6527" txt_f="6529">17</offsets></xref><offsets xml_i="11611" xml_f="11770" txt_i="6529" txt_f="6688"> evidence of MGD based on the number of functional MGs ≤6 (meibomian glands yielding liquid secretion [MGYLS] using the MG evaluator [MGE; TearScience, Inc.]);</offsets><xref rid="b18-opth-12-161" ref-type="bibr"><offsets xml_i="11814" xml_f="11816" txt_i="6688" txt_f="6690">18</offsets></xref><offsets xml_i="11823" xml_f="12171" txt_i="6690" txt_f="7038"> no previous history of allergy or sensitivity to doxycycline; no use of additional anti-inflammatory agents for the prior 3 months. To ensure equivalence between the two groups regarding the likelihood of improvement, both lower eyelids of all subjects were required to have ≥50% observable MG structure determined by retroillumination meiboscopy.</offsets></p></sec><sec><title><offsets xml_i="12193" xml_f="12211" txt_i="7040" txt_f="7058">Exclusion criteria</offsets></title><p><offsets xml_i="12222" xml_f="12522" txt_i="7059" txt_f="7359">Subjects were excluded if there was any evidence of coexisting ocular conditions that may potentially pose an increased risk of procedure-related injury, limit the effectiveness of treatment or interfere with its assessment. These ocular conditions included active ocular inflammation in either eye, </offsets><italic><offsets xml_i="12530" xml_f="12537" txt_i="7359" txt_f="7366">Demodex</offsets></italic><offsets xml_i="12546" xml_f="13077" txt_i="7366" txt_f="7897"> blepharitis, ocular surgery within the past 3 months of baseline examination, or structural ocular surface and eyelid abnormalities. In addition, patients with Sjögren’s syndrome, rheumatoid arthritis, systemic disease resulting in dry eye, known autoimmune disease, doxycycline allergy or sensitivity, history of antibiotic therapy at any time within 2 weeks of the commencement of study and those using significant calcium supplementation or other medications that could interfere with doxycycline absorption were also excluded.</offsets></p></sec><sec><title><offsets xml_i="13099" xml_f="13119" txt_i="7899" txt_f="7919">Adjunctive treatment</offsets></title><p><offsets xml_i="13130" xml_f="13476" txt_i="7920" txt_f="8266">Subjects were requested to continue using any previously used adjunctive therapy in the same manner as long as they already had been using it for a minimum of 3 months (for instance, artificial tears and/or fish oil supplements, lid scrubs and warm compresses). Starting a new adjunctive therapy for MGD during the study period was not permitted.</offsets></p></sec><sec sec-type="methods"><title><offsets xml_i="13517" xml_f="13533" txt_i="8268" txt_f="8284">Study end points</offsets></title><p><offsets xml_i="13544" xml_f="13815" txt_i="8285" txt_f="8556">The primary end points of the study were SPEED and MG function (MGYLS) scores. Additional study parameters included tear breakup time (TBUT), corneal and conjunctival staining and slit-lamp examination. All subjects were evaluated at baseline and 3 months post treatment.</offsets></p><p><offsets xml_i="13822" xml_f="14055" txt_i="8557" txt_f="8790">The SPEED questionnaire evaluated the frequency and severity of dry eye symptoms over the past 3 months. The total SPEED score was calculated as the sum of the frequency and severity scores for all symptoms over a range from 0 to 28.</offsets></p><p><offsets xml_i="14062" xml_f="14224" txt_i="8791" txt_f="8953">The MG assessment was performed at a slit lamp using a hand-held instrument, the MGE (TearScience, Inc.), to ensure consistency of pressure applied to the glands.</offsets><xref rid="b4-opth-12-161" ref-type="bibr"><offsets xml_i="14267" xml_f="14268" txt_i="8953" txt_f="8954">4</offsets></xref><offsets xml_i="14275" xml_f="14276" txt_i="8954" txt_f="8955">,</offsets><xref rid="b19-opth-12-161" ref-type="bibr"><offsets xml_i="14320" xml_f="14322" txt_i="8955" txt_f="8957">19</offsets></xref><offsets xml_i="14329" xml_f="14422" txt_i="8957" txt_f="9050"> The MGE approximates the force of a deliberate blink in yielding secretions from the glands.</offsets><xref rid="b18-opth-12-161" ref-type="bibr"><offsets xml_i="14466" xml_f="14468" txt_i="9050" txt_f="9052">18</offsets></xref><offsets xml_i="14475" xml_f="14643" txt_i="9052" txt_f="9220"> This instrument was held in place for 10–15 seconds, while the number of MGs expressing clear liquid secretions along the entire lower eyelid was counted and recorded.</offsets></p><p><offsets xml_i="14650" xml_f="14790" txt_i="9221" txt_f="9361">TBUT was performed with Dry Eye Test (DET) fluorescein strips (Amcon Laboratories, St Louis, MO, USA) using previously described DET method.</offsets><xref rid="b20-opth-12-161" ref-type="bibr"><offsets xml_i="14834" xml_f="14836" txt_i="9361" txt_f="9363">20</offsets></xref><offsets xml_i="14843" xml_f="15471" txt_i="9363" txt_f="9991"> The DET strip was moistened with a single drop of saline and held vertically to allow the excess saline to run off. Patients were instructed to look down and toward the hand opposite to the eye receiving the stain. After retracting the upper eyelid, the strip was applied to superior temporal bulbar conjunctiva. To observe fluorescein breakup, the standard slit-lamp cobalt blue filter was used. Tear film breakup was defined as the first observed breakup of the tear film following the third blink. The measurements were recorded with the help of a stop watch, and an average of three readings was obtained for data analysis.</offsets></p><p><offsets xml_i="15478" xml_f="15986" txt_i="9992" txt_f="10500">For corneal and conjunctival staining, the respective dyes were instilled using commercially available saline and standard fluorescein (Akorn, Inc., Farmington, CT, USA) and lissamine green strips (Bernell Corporation, Mishawaka, IN, USA). Each strip was moistened with a single drop of saline. The moistened strips were used to place the stain in the inferior cul-de-sac of each eye. After waiting for 90 seconds post dye instillation, the ocular surface (cornea and conjunctiva) was evaluated for staining.</offsets></p><p><offsets xml_i="15993" xml_f="16097" txt_i="10501" txt_f="10605">Based on the report of the National Eye Institute/Industry (NEI) Workshop on Clinical Trials in Dry Eye,</offsets><xref rid="b21-opth-12-161" ref-type="bibr"><offsets xml_i="16141" xml_f="16143" txt_i="10605" txt_f="10607">21</offsets></xref><offsets xml_i="16150" xml_f="16451" txt_i="10607" txt_f="10908"> corneal fluorescein (CF) staining was graded in five regions of the cornea on a scale of 0 (none) to 3 (severe) with a total score of 15. Conjunctival lissamine green (CLG) staining was graded on a scale of 0 (none) to 3 (severe) over six regions of the conjunctiva, with scores ranging from 0 to 18.</offsets></p></sec><sec><title><offsets xml_i="16473" xml_f="16491" txt_i="10910" txt_f="10928">LipiFlow procedure</offsets></title><p><offsets xml_i="16502" xml_f="16744" txt_i="10929" txt_f="11171">In the subjects randomized to receive the LipiFlow, the procedures were administered in accordance with the device labeling. The LipiFlow, designed to heat and simultaneously evacuate the MG contents, has been extensively described elsewhere.</offsets><xref rid="b4-opth-12-161" ref-type="bibr"><offsets xml_i="16787" xml_f="16788" txt_i="11171" txt_f="11172">4</offsets></xref><offsets xml_i="16795" xml_f="17456" txt_i="11172" txt_f="11833"> In brief, one to two drops of topical anesthesia were applied prior to the bilateral application of the activators. The inner portion of the activator applied a constant temperature of 42.5°C to the tarsal conjunctiva of upper and lower eyelids. Simultaneously, the outer portion of the activator applied directional, pulsatile pressure to the external eyelid surfaces (maximum 6 psi) for the 12-minute treatment cycle. Consequently, the subjects felt warmth and pressure on their eyelids during the 12-minute bilateral procedure. All subjects were monitored throughout the process, and both the eyes were examined at the slit lamp at the end of the procedure.</offsets></p></sec><sec sec-type="methods"><title><offsets xml_i="17497" xml_f="17517" txt_i="11835" txt_f="11855">Statistical analysis</offsets></title><p><offsets xml_i="17528" xml_f="17754" txt_i="11856" txt_f="12082">The study sample size was based on a power analysis of the primary study end points and the null hypothesis that the single VTP treatment would be non-inferior to the 3-month daily dose of doxycycline (power 80%, alpha =0.05).</offsets></p><p><offsets xml_i="17761" xml_f="18205" txt_i="12083" txt_f="12524">Data analysis was performed using SPSS software for Windows version 17.0 (SPSS Inc., Chicago, IL, USA). The data were examined for outliers using outlier labeling method with a multiplier of 2.2, and one outlier was removed from the analysis of SPEED scores of the VTP treatment group. The normality of data was checked using Shapiro–Wilk test, and a threshold of &lt;0.05 was considered significant. For normally distributed data, independent </offsets><italic><offsets xml_i="18213" xml_f="18214" txt_i="12524" txt_f="12525">t</offsets></italic><offsets xml_i="18223" xml_f="18240" txt_i="12525" txt_f="12542">-test and paired </offsets><italic><offsets xml_i="18248" xml_f="18249" txt_i="12542" txt_f="12543">t</offsets></italic><offsets xml_i="18258" xml_f="18406" txt_i="12543" txt_f="12691">-test were used for comparison between the groups and within the group, respectively; otherwise, their nonparametric counterparts, ie, Mann–Whitney </offsets><italic><offsets xml_i="18414" xml_f="18415" txt_i="12691" txt_f="12692">U</offsets></italic><offsets xml_i="18424" xml_f="18477" txt_i="12692" txt_f="12745"> test and Wilcoxon signed-rank test had been used. A </offsets><italic><offsets xml_i="18485" xml_f="18486" txt_i="12745" txt_f="12746">p</offsets></italic><offsets xml_i="18495" xml_f="18555" txt_i="12746" txt_f="12803">-value of &lt;0.05 was considered statistically significant.</offsets></p></sec></sec><sec sec-type="results"><title><offsets xml_i="18602" xml_f="18609" txt_i="12806" txt_f="12813">Results</offsets></title><p><offsets xml_i="18620" xml_f="19014" txt_i="12814" txt_f="13208">Of the 28 subjects recruited in the study, two subjects in the doxycycline group discontinued their treatment regimen due to stomach upset/intolerance to study medication and one in the VTP group was lost to follow up. Therefore, these subjects were removed from the analysis. The mean age of subjects included in the VTP and doxycycline groups was 51.7±15.6 and 50.4±14.4 years, respectively (</offsets><italic><offsets xml_i="19022" xml_f="19023" txt_i="13208" txt_f="13209">p</offsets></italic><offsets xml_i="19032" xml_f="19118" txt_i="13209" txt_f="13295">=0.84). At baseline, all the study parameters were comparable between the two groups (</offsets><xref ref-type="table" rid="t1-opth-12-161"><offsets xml_i="19162" xml_f="19169" txt_i="13295" txt_f="13302">Table 1</offsets></xref><offsets xml_i="19176" xml_f="19178" txt_i="13302" txt_f="13304">).</offsets></p><p><offsets xml_i="19185" xml_f="19300" txt_i="13305" txt_f="13420">At 3 months, SPEED scores, MGYLS and TBUT were significantly improved from their baseline levels in the VTP group (</offsets><italic><offsets xml_i="19308" xml_f="19309" txt_i="13420" txt_f="13421">p</offsets></italic><offsets xml_i="19318" xml_f="19329" txt_i="13421" txt_f="13429">&lt;0.005; </offsets><xref ref-type="fig" rid="f1-opth-12-161"><offsets xml_i="19371" xml_f="19380" txt_i="13429" txt_f="13438">Figures 1</offsets></xref><xref ref-type="fig" rid="f2-opth-12-161"></xref><offsets xml_i="19436" xml_f="19437" txt_i="13438" txt_f="13439">–</offsets><xref ref-type="fig" rid="f3-opth-12-161"><offsets xml_i="19479" xml_f="19480" txt_i="13439" txt_f="13440">3</offsets></xref><offsets xml_i="19487" xml_f="19578" txt_i="13440" txt_f="13531">). Similarly, there was a significant improvement in CF and CLG staining in the VTP group (</offsets><italic><offsets xml_i="19586" xml_f="19587" txt_i="13531" txt_f="13532">p</offsets></italic><offsets xml_i="19596" xml_f="19607" txt_i="13532" txt_f="13543">=0.020 and </offsets><italic><offsets xml_i="19615" xml_f="19616" txt_i="13543" txt_f="13544">p</offsets></italic><offsets xml_i="19625" xml_f="19695" txt_i="13544" txt_f="13614">=0.002, respectively). In the doxycycline group, SPEED scores, MGYLS (</offsets><xref ref-type="fig" rid="f1-opth-12-161"><offsets xml_i="19737" xml_f="19746" txt_i="13614" txt_f="13623">Figures 1</offsets></xref><offsets xml_i="19753" xml_f="19758" txt_i="13623" txt_f="13628"> and </offsets><xref ref-type="fig" rid="f2-opth-12-161"><offsets xml_i="19800" xml_f="19801" txt_i="13628" txt_f="13629">2</offsets></xref><offsets xml_i="19808" xml_f="19882" txt_i="13629" txt_f="13703">) and CLG staining improved significantly from their pretreatment levels (</offsets><italic><offsets xml_i="19890" xml_f="19891" txt_i="13703" txt_f="13704">p</offsets></italic><offsets xml_i="19900" xml_f="19941" txt_i="13704" txt_f="13742">&lt;0.005), but the improvement in TBUT (</offsets><xref ref-type="fig" rid="f3-opth-12-161"><offsets xml_i="19983" xml_f="19991" txt_i="13742" txt_f="13750">Figure 3</offsets></xref><offsets xml_i="19998" xml_f="20056" txt_i="13750" txt_f="13808">) and CF staining did not reach statistical significance (</offsets><italic><offsets xml_i="20064" xml_f="20065" txt_i="13808" txt_f="13809">p</offsets></italic><offsets xml_i="20074" xml_f="20085" txt_i="13809" txt_f="13820">=0.262 and </offsets><italic><offsets xml_i="20093" xml_f="20094" txt_i="13820" txt_f="13821">p</offsets></italic><offsets xml_i="20103" xml_f="20125" txt_i="13821" txt_f="13843">=0.414, respectively).</offsets></p><p><offsets xml_i="20132" xml_f="20306" txt_i="13844" txt_f="14018">Specifically, at 3 months, the mean SPEED scores (5.42±2.15), MGYLS (7.73±5.53) and TBUT (8.44±1.81) were significantly improved from their baseline levels in the VTP group (</offsets><italic><offsets xml_i="20314" xml_f="20315" txt_i="14018" txt_f="14019">p</offsets></italic><offsets xml_i="20324" xml_f="20335" txt_i="14019" txt_f="14027">&lt;0.005; </offsets><xref ref-type="fig" rid="f1-opth-12-161"><offsets xml_i="20377" xml_f="20386" txt_i="14027" txt_f="14036">Figures 1</offsets></xref><xref ref-type="fig" rid="f2-opth-12-161"></xref><offsets xml_i="20442" xml_f="20443" txt_i="14036" txt_f="14037">–</offsets><xref ref-type="fig" rid="f3-opth-12-161"><offsets xml_i="20485" xml_f="20486" txt_i="14037" txt_f="14038">3</offsets></xref><offsets xml_i="20493" xml_f="20609" txt_i="14038" txt_f="14154">). Similarly, there was a significant improvement in CF and CLG staining in the VTP group (0.12±0.33 and 0.62±0.83; </offsets><italic><offsets xml_i="20617" xml_f="20618" txt_i="14154" txt_f="14155">p</offsets></italic><offsets xml_i="20627" xml_f="20638" txt_i="14155" txt_f="14166">=0.020 and </offsets><italic><offsets xml_i="20646" xml_f="20647" txt_i="14166" txt_f="14167">p</offsets></italic><offsets xml_i="20656" xml_f="20751" txt_i="14167" txt_f="14262">=0.002, respectively). In the doxycycline group, SPEED scores (9.42±5.47), MGYLS (10.63±5.95) (</offsets><xref ref-type="fig" rid="f1-opth-12-161"><offsets xml_i="20793" xml_f="20802" txt_i="14262" txt_f="14271">Figures 1</offsets></xref><offsets xml_i="20809" xml_f="20814" txt_i="14271" txt_f="14276"> and </offsets><xref ref-type="fig" rid="f2-opth-12-161"><offsets xml_i="20856" xml_f="20857" txt_i="14276" txt_f="14277">2</offsets></xref><offsets xml_i="20864" xml_f="20964" txt_i="14277" txt_f="14377">, respectively) and CLG staining (1.13±1.51) improved significantly from their pretreatment levels (</offsets><italic><offsets xml_i="20972" xml_f="20973" txt_i="14377" txt_f="14378">p</offsets></italic><offsets xml_i="20982" xml_f="21034" txt_i="14378" txt_f="14427">&lt;0.005), but the improvement in TBUT (7.59±2.03; </offsets><xref ref-type="fig" rid="f3-opth-12-161"><offsets xml_i="21076" xml_f="21084" txt_i="14427" txt_f="14435">Figure 3</offsets></xref><offsets xml_i="21091" xml_f="21161" txt_i="14435" txt_f="14505">) and CF staining (0.13±0.34) did not reach statistical significance (</offsets><italic><offsets xml_i="21169" xml_f="21170" txt_i="14505" txt_f="14506">p</offsets></italic><offsets xml_i="21179" xml_f="21190" txt_i="14506" txt_f="14517">=0.262 and </offsets><italic><offsets xml_i="21198" xml_f="21199" txt_i="14517" txt_f="14518">p</offsets></italic><offsets xml_i="21208" xml_f="21230" txt_i="14518" txt_f="14540">=0.414, respectively).</offsets></p><p><offsets xml_i="21237" xml_f="21390" txt_i="14541" txt_f="14694">Comparison between the two groups at 3 months revealed that the mean SPEED scores of the VTP group were significantly better than the doxycycline group (</offsets><italic><offsets xml_i="21398" xml_f="21399" txt_i="14694" txt_f="14695">p</offsets></italic><offsets xml_i="21408" xml_f="21416" txt_i="14695" txt_f="14703">=0.03) (</offsets><xref ref-type="fig" rid="f1-opth-12-161"><offsets xml_i="21458" xml_f="21466" txt_i="14703" txt_f="14711">Figure 1</offsets></xref><offsets xml_i="21473" xml_f="21543" txt_i="14711" txt_f="14781">). MGYLS and TBUT were found to be comparable between the two groups (</offsets><italic><offsets xml_i="21551" xml_f="21552" txt_i="14781" txt_f="14782">p</offsets></italic><offsets xml_i="21561" xml_f="21572" txt_i="14782" txt_f="14793">=0.096 and </offsets><italic><offsets xml_i="21580" xml_f="21581" txt_i="14793" txt_f="14794">p</offsets></italic><offsets xml_i="21590" xml_f="21612" txt_i="14794" txt_f="14816">=0.155, respectively; </offsets><xref ref-type="fig" rid="f2-opth-12-161"><offsets xml_i="21654" xml_f="21663" txt_i="14816" txt_f="14825">Figures 2</offsets></xref><offsets xml_i="21670" xml_f="21675" txt_i="14825" txt_f="14830"> and </offsets><xref ref-type="fig" rid="f3-opth-12-161"><offsets xml_i="21717" xml_f="21718" txt_i="14830" txt_f="14831">3</offsets></xref><offsets xml_i="21725" xml_f="21861" txt_i="14831" txt_f="14967">). Similarly, the two groups were comparable for CF staining (0.12±0.33 and 0.13±0.34 for the VTP and doxycycline groups, respectively; </offsets><italic><offsets xml_i="21869" xml_f="21870" txt_i="14967" txt_f="14968">p</offsets></italic><offsets xml_i="21879" xml_f="21979" txt_i="14968" txt_f="15068">=0.918) and CLG staining (0.62±0.85 and 1.13±1.51 for the VTP and doxycycline groups, respectively; </offsets><italic><offsets xml_i="21987" xml_f="21988" txt_i="15068" txt_f="15069">p</offsets></italic><offsets xml_i="21997" xml_f="22005" txt_i="15069" txt_f="15077">=0.299).</offsets></p></sec><sec sec-type="discussion"><title><offsets xml_i="22049" xml_f="22059" txt_i="15079" txt_f="15089">Discussion</offsets></title><p><offsets xml_i="22070" xml_f="22159" txt_i="15090" txt_f="15179">The doxycycline outcomes in the current study were similar to those published previously.</offsets><xref rid="b12-opth-12-161" ref-type="bibr"><offsets xml_i="22203" xml_f="22205" txt_i="15179" txt_f="15181">12</offsets></xref><offsets xml_i="22212" xml_f="22213" txt_i="15181" txt_f="15182">–</offsets><xref rid="b16-opth-12-161" ref-type="bibr"><offsets xml_i="22257" xml_f="22259" txt_i="15182" txt_f="15184">16</offsets></xref><offsets xml_i="22266" xml_f="22476" txt_i="15184" txt_f="15394"> Subjective symptom scores (assessed using different scales) have been reported to significantly improve following 3–4 weeks of doxycycline treatment regimens, using doses as high as 400 mg doxycycline per day.</offsets><xref rid="b14-opth-12-161" ref-type="bibr"><offsets xml_i="22520" xml_f="22522" txt_i="15394" txt_f="15396">14</offsets></xref><offsets xml_i="22529" xml_f="22530" txt_i="15396" txt_f="15397">–</offsets><xref rid="b16-opth-12-161" ref-type="bibr"><offsets xml_i="22574" xml_f="22576" txt_i="15397" txt_f="15399">16</offsets></xref><offsets xml_i="22583" xml_f="22732" txt_i="15399" txt_f="15548"> In addition, daily administration of 200 mg oral doxycycline (100 mg BID for 1–2 months) has been found to improve meibomian gland secretion scores.</offsets><xref rid="b12-opth-12-161" ref-type="bibr"><offsets xml_i="22776" xml_f="22778" txt_i="15548" txt_f="15550">12</offsets></xref><offsets xml_i="22785" xml_f="22786" txt_i="15550" txt_f="15551">,</offsets><xref rid="b14-opth-12-161" ref-type="bibr"><offsets xml_i="22830" xml_f="22832" txt_i="15551" txt_f="15553">14</offsets></xref><offsets xml_i="22839" xml_f="23455" txt_i="15553" txt_f="16169"> In this study, a standardized amount of pressure, approximating a deliberate blink, was applied over the glands as opposed to the more variable “mild” or “firm” pressure as described in other studies evaluating the benefits of treating MGD with doxycycline. The standardized pressure with the MGE used in this study better represents the “functional” status of the MG, ie, the ability of the gland to release liquid during the blinking process. Using the standardized pressure provided by the MGE, these study results corroborate some previous studies showing that doxycycline can improve meibomian gland secretion.</offsets><xref rid="b12-opth-12-161" ref-type="bibr"><offsets xml_i="23499" xml_f="23501" txt_i="16169" txt_f="16171">12</offsets></xref><offsets xml_i="23508" xml_f="23509" txt_i="16171" txt_f="16172">,</offsets><xref rid="b14-opth-12-161" ref-type="bibr"><offsets xml_i="23553" xml_f="23555" txt_i="16172" txt_f="16174">14</offsets></xref></p><p><offsets xml_i="23569" xml_f="23660" txt_i="16175" txt_f="16266">Doxycycline treatment has also been reported to significantly improve TBUT in some studies;</offsets><xref rid="b12-opth-12-161" ref-type="bibr"><offsets xml_i="23704" xml_f="23706" txt_i="16266" txt_f="16268">12</offsets></xref><offsets xml_i="23713" xml_f="23714" txt_i="16268" txt_f="16269">,</offsets><xref rid="b15-opth-12-161" ref-type="bibr"><offsets xml_i="23758" xml_f="23760" txt_i="16269" txt_f="16271">15</offsets></xref><offsets xml_i="23767" xml_f="23784" txt_i="16271" txt_f="16288"> Kashkouli et al,</offsets><xref rid="b14-opth-12-161" ref-type="bibr"><offsets xml_i="23828" xml_f="23830" txt_i="16288" txt_f="16290">14</offsets></xref><offsets xml_i="23837" xml_f="24215" txt_i="16290" txt_f="16668"> in contrast, reported slight decrease in TBUT. The 3-month course of doxycycline in the current study did not show statistically significant improvement in TBUT. To the best of our knowledge, the outcomes of conjunctival staining have not been studied following doxycycline therapy; the mean CLG scores were significantly improved in the current study. Of note, Kashkouli et al</offsets><xref rid="b14-opth-12-161" ref-type="bibr"><offsets xml_i="24259" xml_f="24261" txt_i="16668" txt_f="16670">14</offsets></xref><offsets xml_i="24268" xml_f="24672" txt_i="16670" txt_f="17074"> reported the outcomes for ocular surface staining that included the assessment of the entire cornea as well as nasal and temporal interpalpebral conjunctival regions, graded using a modified 4-point categorical scale (grade 0–3). The mean ocular surface staining scores were found to improve significantly following doxycycline therapy (100 mg BID for 1 month). Regarding corneal staining, Zandian et al</offsets><xref rid="b16-opth-12-161" ref-type="bibr"><offsets xml_i="24716" xml_f="24718" txt_i="17074" txt_f="17076">16</offsets></xref><offsets xml_i="24725" xml_f="25256" txt_i="17076" txt_f="17607"> reported significant improvement in the mean corneal staining scores with oral doxycycline therapy (100 mg daily for 3 weeks). Similarly, The mean corneal staining score improvement in the doxycycline group of the current study was not statistically significant. Overall, the differences may be explained, in part, by different grading methods, especially for MGD which has evolved significantly in the past few years, different levels of severity of MGD and dry eye-associated anatomical changes in the ocular surface and eyelid.</offsets></p><p><offsets xml_i="25263" xml_f="25436" txt_i="17608" txt_f="17781">The outcomes of a single VTP procedure in the current study are in alignment with the numerous other studies documenting a predictably significant improvement in MG function</offsets><xref rid="b4-opth-12-161" ref-type="bibr"><offsets xml_i="25479" xml_f="25480" txt_i="17781" txt_f="17782">4</offsets></xref><offsets xml_i="25487" xml_f="25488" txt_i="17782" txt_f="17783">,</offsets><xref rid="b22-opth-12-161" ref-type="bibr"><offsets xml_i="25532" xml_f="25534" txt_i="17783" txt_f="17785">22</offsets></xref><offsets xml_i="25541" xml_f="25542" txt_i="17785" txt_f="17786">,</offsets><xref rid="b23-opth-12-161" ref-type="bibr"><offsets xml_i="25586" xml_f="25588" txt_i="17786" txt_f="17788">23</offsets></xref><offsets xml_i="25595" xml_f="25629" txt_i="17788" txt_f="17822"> and reduction in dry eye symptoms</offsets><xref rid="b4-opth-12-161" ref-type="bibr"><offsets xml_i="25672" xml_f="25673" txt_i="17822" txt_f="17823">4</offsets></xref><offsets xml_i="25680" xml_f="25681" txt_i="17823" txt_f="17824">,</offsets><xref rid="b9-opth-12-161" ref-type="bibr"><offsets xml_i="25724" xml_f="25725" txt_i="17824" txt_f="17825">9</offsets></xref><offsets xml_i="25732" xml_f="25733" txt_i="17825" txt_f="17826">,</offsets><xref rid="b19-opth-12-161" ref-type="bibr"><offsets xml_i="25777" xml_f="25779" txt_i="17826" txt_f="17828">19</offsets></xref><offsets xml_i="25786" xml_f="25787" txt_i="17828" txt_f="17829">,</offsets><xref rid="b22-opth-12-161" ref-type="bibr"><offsets xml_i="25831" xml_f="25833" txt_i="17829" txt_f="17831">22</offsets></xref><offsets xml_i="25840" xml_f="25841" txt_i="17831" txt_f="17832">,</offsets><xref rid="b24-opth-12-161" ref-type="bibr"><offsets xml_i="25885" xml_f="25887" txt_i="17832" txt_f="17834">24</offsets></xref><offsets xml_i="25894" xml_f="26001" txt_i="17834" txt_f="17941"> after a single VTP treatment. While several studies also report significant improvement in TBUT after VTP,</offsets><xref rid="b4-opth-12-161" ref-type="bibr"><offsets xml_i="26044" xml_f="26045" txt_i="17941" txt_f="17942">4</offsets></xref><offsets xml_i="26052" xml_f="26053" txt_i="17942" txt_f="17943">,</offsets><xref rid="b23-opth-12-161" ref-type="bibr"><offsets xml_i="26097" xml_f="26099" txt_i="17943" txt_f="17945">23</offsets></xref><offsets xml_i="26106" xml_f="26195" txt_i="17945" txt_f="18034"> there are some that were not able to show statistically significant improvement in TBUT.</offsets><xref rid="b22-opth-12-161" ref-type="bibr"><offsets xml_i="26239" xml_f="26241" txt_i="18034" txt_f="18036">22</offsets></xref><offsets xml_i="26248" xml_f="26249" txt_i="18036" txt_f="18037">,</offsets><xref rid="b24-opth-12-161" ref-type="bibr"><offsets xml_i="26293" xml_f="26295" txt_i="18037" txt_f="18039">24</offsets></xref><offsets xml_i="26302" xml_f="26303" txt_i="18039" txt_f="18040">,</offsets><xref rid="b25-opth-12-161" ref-type="bibr"><offsets xml_i="26347" xml_f="26349" txt_i="18040" txt_f="18042">25</offsets></xref><offsets xml_i="26356" xml_f="26565" txt_i="18042" txt_f="18251"> The results of the current study demonstrated significant improvement in TBUT in the VTP-treated eyes. The mean corneal staining scores have been reported to improve significantly following the VTP procedure.</offsets><xref rid="b4-opth-12-161" ref-type="bibr"><offsets xml_i="26608" xml_f="26609" txt_i="18251" txt_f="18252">4</offsets></xref><offsets xml_i="26616" xml_f="26617" txt_i="18252" txt_f="18253">,</offsets><xref rid="b23-opth-12-161" ref-type="bibr"><offsets xml_i="26661" xml_f="26663" txt_i="18253" txt_f="18255">23</offsets></xref><offsets xml_i="26670" xml_f="27012" txt_i="18255" txt_f="18597"> Similarly, the mean CF staining scores improved significantly in the VTP group of the current study. The conjunctival staining has not been studied extensively in the previous literature; a single study reported small but statistically significant increase in the mean conjunctival staining scores in the VTP group, at 4 weeks from baseline.</offsets><xref rid="b4-opth-12-161" ref-type="bibr"><offsets xml_i="27055" xml_f="27056" txt_i="18597" txt_f="18598">4</offsets></xref><offsets xml_i="27063" xml_f="27225" txt_i="18598" txt_f="18760"> As expected from the overall improvement in ocular surface health in the VTP group of the current study, we found significant improvement in the mean CLG scores.</offsets></p><p><offsets xml_i="27232" xml_f="27826" txt_i="18761" txt_f="19355">The mean MGYLS scores of the two groups were found to be not statistically significantly different from one another both pre and post treatment. The VTP procedure is known to improve the MG function, so the study results are in alignment with what would be expected. The improvement in gland function as a result of the daily use of doxycycline for 3 months was not as clearly predicted by the literature. The previously reported favorable biochemical changes in MGSs following systemic tetracycline analog administration may explain the improvement in gland function. For example, Foulks et al</offsets><xref rid="b12-opth-12-161" ref-type="bibr"><offsets xml_i="27870" xml_f="27872" txt_i="19355" txt_f="19357">12</offsets></xref><offsets xml_i="27879" xml_f="28040" txt_i="19357" txt_f="19518"> reported changes in the characteristics and biochemical composition of MGSs following 4 weeks of oral doxycycline treatment in patients with MGD. Souchier et al</offsets><xref rid="b26-opth-12-161" ref-type="bibr"><offsets xml_i="28084" xml_f="28086" txt_i="19518" txt_f="19520">26</offsets></xref><offsets xml_i="28093" xml_f="28454" txt_i="19520" txt_f="19881"> reported alterations in the meibomian fatty acid composition after 8-week therapy with minocycline, a tetracycline analog similar to doxycycline. Branched chain fatty acids (BCFAs), particularly isoC20, were found to be decreased. Higher levels of BCFAs are assumed to have detrimental effect on MG epithelium and been correlated with the keratinization of MG.</offsets><xref rid="b27-opth-12-161" ref-type="bibr"><offsets xml_i="28498" xml_f="28500" txt_i="19881" txt_f="19883">27</offsets></xref><offsets xml_i="28507" xml_f="28724" txt_i="19883" txt_f="20100"> It has been hypothesized that lower levels of BCFAs and correspondingly higher levels of C16 and C18 saturated fatty acids may enhance the fluidity and stability of the tear film, thus improving the dry eye symptoms.</offsets><xref rid="b26-opth-12-161" ref-type="bibr"><offsets xml_i="28768" xml_f="28770" txt_i="20100" txt_f="20102">26</offsets></xref></p><p><offsets xml_i="28784" xml_f="29679" txt_i="20103" txt_f="20998">While this study demonstrates that the daily use of doxycycline for 3 months can improve the signs and symptoms of moderate-to-severe MGD, the use of doxycycline is not without complication. There are many known side effects which serve to decrease patient compliance and may result in the termination of treatment altogether. This was evidenced in the current study; two subjects (14%) in the doxycycline group discontinued their treatment regimen due to stomach upset/intolerance to study medication. Previous publications reporting on the use of doxycycline for dry eye have documented numerous side effects, such as gastrointestinal problems (esophagitis, nausea, dyspepsia, diarrhea, abdominal cramps and decreased appetite), dermatological effects (itchy skin, urticaria and erythematous papules), hypersensitivity reactions (allergy and fever), increased tendency to bleed and stomatitis.</offsets><xref rid="b14-opth-12-161" ref-type="bibr"><offsets xml_i="29723" xml_f="29725" txt_i="20998" txt_f="21000">14</offsets></xref><offsets xml_i="29732" xml_f="29733" txt_i="21000" txt_f="21001">,</offsets><xref rid="b15-opth-12-161" ref-type="bibr"><offsets xml_i="29777" xml_f="29779" txt_i="21001" txt_f="21003">15</offsets></xref><offsets xml_i="29786" xml_f="29856" txt_i="21003" txt_f="21073"> Doxycycline has also been linked to liver failure and teratogenicity.</offsets><xref rid="b28-opth-12-161" ref-type="bibr"><offsets xml_i="29900" xml_f="29902" txt_i="21073" txt_f="21075">28</offsets></xref><offsets xml_i="29909" xml_f="30039" txt_i="21075" txt_f="21205"> Depending upon the dose and duration of doxycycline treatment, side effects have been reported in as high as 40% of the subjects.</offsets><xref rid="b14-opth-12-161" ref-type="bibr"><offsets xml_i="30083" xml_f="30085" txt_i="21205" txt_f="21207">14</offsets></xref><offsets xml_i="30092" xml_f="30093" txt_i="21207" txt_f="21208">,</offsets><xref rid="b15-opth-12-161" ref-type="bibr"><offsets xml_i="30137" xml_f="30139" txt_i="21208" txt_f="21210">15</offsets></xref><offsets xml_i="30146" xml_f="30438" txt_i="21210" txt_f="21502"> In addition, medical literature outside ophthalmology has reported some rare side effects such as esophageal ulcers, light-sensitive eruptions, photo-onycholysis and hypersensitivity syndrome reactions, single organ dysfunction and serum sickness such as reaction with doxycycline treatment.</offsets><xref rid="b29-opth-12-161" ref-type="bibr"><offsets xml_i="30482" xml_f="30484" txt_i="21502" txt_f="21504">29</offsets></xref><offsets xml_i="30491" xml_f="30492" txt_i="21504" txt_f="21505">–</offsets><xref rid="b33-opth-12-161" ref-type="bibr"><offsets xml_i="30536" xml_f="30538" txt_i="21505" txt_f="21507">33</offsets></xref><offsets xml_i="30545" xml_f="30708" txt_i="21507" txt_f="21670"> Its long-term use has been related to potential development of bacterial resistance and increased risk of secondary infections with other organisms (particularly </offsets><italic><offsets xml_i="30716" xml_f="30723" txt_i="21670" txt_f="21677">Candida</offsets></italic><offsets xml_i="30732" xml_f="30738" txt_i="21677" txt_f="21683"> sp.).</offsets><xref rid="b34-opth-12-161" ref-type="bibr"><offsets xml_i="30782" xml_f="30784" txt_i="21683" txt_f="21685">34</offsets></xref><offsets xml_i="30791" xml_f="31058" txt_i="21685" txt_f="21952"> Sub-microbial dosing of doxycycline has been advocated to lessen side effects and risk of microbial resistance, but even at low doses nasopharyngitis, diarrhea, headache, hypertension, aspartate aminotransferase (AST) elevation and abdominal pain have been reported.</offsets><xref rid="b15-opth-12-161" ref-type="bibr"><offsets xml_i="31102" xml_f="31104" txt_i="21952" txt_f="21954">15</offsets></xref><offsets xml_i="31111" xml_f="31112" txt_i="21954" txt_f="21955">,</offsets><xref rid="b35-opth-12-161" ref-type="bibr"><offsets xml_i="31156" xml_f="31158" txt_i="21955" txt_f="21957">35</offsets></xref></p><p><offsets xml_i="31172" xml_f="31453" txt_i="21958" txt_f="22239">As a chronic and progressive condition, MGD requires long-term management. The long-term safety concerns with doxycycline use render it a short-term, albeit sometimes necessary, option at best. In contrast, the VTP procedure lasts only 12 minutes, has an exceptional safety profile</offsets><xref rid="b4-opth-12-161" ref-type="bibr"><offsets xml_i="31496" xml_f="31497" txt_i="22239" txt_f="22240">4</offsets></xref><offsets xml_i="31504" xml_f="31505" txt_i="22240" txt_f="22241">,</offsets><xref rid="b22-opth-12-161" ref-type="bibr"><offsets xml_i="31549" xml_f="31551" txt_i="22241" txt_f="22243">22</offsets></xref><offsets xml_i="31558" xml_f="31710" txt_i="22243" txt_f="22395"> and has been shown to result in sustained clinically significant improvement in gland function and reduced dry eye symptoms observed over 12–36 months.</offsets><xref rid="b5-opth-12-161" ref-type="bibr"><offsets xml_i="31753" xml_f="31754" txt_i="22395" txt_f="22396">5</offsets></xref><offsets xml_i="31761" xml_f="31762" txt_i="22396" txt_f="22397">,</offsets><xref rid="b9-opth-12-161" ref-type="bibr"><offsets xml_i="31805" xml_f="31806" txt_i="22397" txt_f="22398">9</offsets></xref><offsets xml_i="31813" xml_f="32025" txt_i="22398" txt_f="22610"> Consistent with the previous findings, no adverse events were found for VTP-treated eyes in this study. A single 12-minute VTP procedure presents a favorable alternative to the long-term use of oral antibiotics.</offsets></p><p></p><p><offsets xml_i="32039" xml_f="32171" txt_i="22612" txt_f="22744">Over its disease course, untreated MGD is considered to result in irreversible anatomical damage to the MGs. Recently, Blackie et al</offsets><xref rid="b5-opth-12-161" ref-type="bibr"><offsets xml_i="32214" xml_f="32215" txt_i="22744" txt_f="22745">5</offsets></xref><offsets xml_i="32222" xml_f="33308" txt_i="22745" txt_f="23831"> provided clinical evidence in support of the hypothesis that early intervention for MGD optimizes the therapeutic outcomes. They reported significant association between greater mean improvement in MGS scores and patient characteristics such as less severe baseline scores and shorter duration of time between the diagnosis and treatment of MGD. In this study, the subjects had more advanced disease prior to treatment. Even so, the results of a single VTP treatment were compelling. Based on these results, one could hypothesize that VTP in combination with short-term doxycycline use may be a highly effective treatment option for more advanced stages of MGD. The authors hypothesize that such a combined approach may induce positive changes in the fatty acid composition of MGSs which may be better amenable to liquefaction and clearance of obstruction by VTP procedure. It could possibly also improve the duration of treatment effect of a single VTP procedure. Future studies are warranted to evaluate the proposed synergistic role of VTP procedure with short-term doxycycline use.</offsets></p></sec><sec><title><offsets xml_i="33330" xml_f="33340" txt_i="23833" txt_f="23843">Conclusion</offsets></title><p><offsets xml_i="33351" xml_f="33926" txt_i="23844" txt_f="24419">In this prospective, randomized, parallel-group, single-masked study, a single 12-minute bilateral VTP procedure was significantly more effective than the 3-month daily course of oral doxycycline at improving the dry eye symptoms secondary to MGD. A single VTP treatment was at least as good as the daily doxycycline in improving MG function and all measured signs of MGD for moderate-to-severe MGD. Given the minimal risk profile of the single VTP procedure over long-term doxycycline use, a single VTP procedure presents a favorable alternative to long-term antibiotic use.</offsets></p></sec></body><back><fn-group><fn fn-type="COI-statement"><p><bold>Disclosure</bold></p><p>RB is a consultant for TearScience, Inc. CAB is an employee of TearScience, Inc. The other authors report no conflicts of interest in this work.</p></fn></fn-group><ref-list><title>References</title><ref id="b1-opth-12-161"><label>1</label><element-citation publication-type="journal"><article-title>The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007)</article-title><source>Ocul Surf</source><year>2007</year><volume>5</volume><issue>2</issue><fpage>75</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">17508116</pub-id></element-citation></ref><ref id="b2-opth-12-161"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nelson</surname><given-names>JD</given-names></name><name><surname>Shimazaki</surname><given-names>J</given-names></name><name><surname>Benitez-del-Castillo</surname><given-names>JM</given-names></name><etal></etal></person-group><article-title>The international workshop on meibomian gland dysfunction: report of the definition and classification subcommittee</article-title><source>Invest Ophthalmol Vis Sci</source><year>2011</year><volume>52</volume><issue>4</issue><fpage>1930</fpage><lpage>1937</lpage><pub-id pub-id-type="pmid">21450914</pub-id></element-citation></ref><ref id="b3-opth-12-161"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blackie</surname><given-names>CA</given-names></name><name><surname>Carlson</surname><given-names>AN</given-names></name><name><surname>Korb</surname><given-names>DR</given-names></name></person-group><article-title>Treatment for meibomian gland dysfunction and dry eye symptoms with a single-dose vectored thermal pulsation: a review</article-title><source>Curr Opin Ophthalmol</source><year>2015</year><volume>26</volume><issue>4</issue><fpage>306</fpage><lpage>313</lpage><pub-id pub-id-type="pmid">26058030</pub-id></element-citation></ref><ref id="b4-opth-12-161"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lane</surname><given-names>SS</given-names></name><name><surname>DuBiner</surname><given-names>HB</given-names></name><name><surname>Epstein</surname><given-names>RJ</given-names></name><etal></etal></person-group><article-title>A new system, the LipiFlow, for the treatment of meibomian gland dysfunction</article-title><source>Cornea</source><year>2012</year><volume>31</volume><issue>4</issue><fpage>396</fpage><lpage>404</lpage><pub-id pub-id-type="pmid">22222996</pub-id></element-citation></ref><ref id="b5-opth-12-161"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blackie</surname><given-names>CA</given-names></name><name><surname>Coleman</surname><given-names>CA</given-names></name><name><surname>Holland</surname><given-names>EJ</given-names></name></person-group><article-title>The sustained effect (12 months) of a single-dose vectored thermal pulsation procedure for meibomian gland dysfunction and evaporative dry eye</article-title><source>Clin Ophthalmol</source><year>2016</year><volume>10</volume><fpage>1385</fpage><lpage>1396</lpage><pub-id pub-id-type="pmid">27555745</pub-id></element-citation></ref><ref id="b6-opth-12-161"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Epitropoulos</surname><given-names>AT</given-names></name><name><surname>Goslin</surname><given-names>K</given-names></name><name><surname>Bedi</surname><given-names>R</given-names></name><name><surname>Blackie</surname><given-names>CA</given-names></name></person-group><article-title>Meibomian gland dysfunction patients with novel Sjogren’s syndrome biomarkers benefit significantly from a single vectored thermal pulsation procedure: a retrospective analysis</article-title><source>Clin Ophthalmol</source><year>2017</year><volume>11</volume><fpage>701</fpage><lpage>706</lpage><pub-id pub-id-type="pmid">28458508</pub-id></element-citation></ref><ref id="b7-opth-12-161"><label>7</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Korb</surname><given-names>D</given-names></name><name><surname>Blackie</surname><given-names>CA</given-names></name></person-group><article-title>Single Lipiflow treatment increases soft contact lens wearing time and reduces lid wiper epitheliopathy and dry eye symptoms</article-title><source>American Academy of Optometry’s 93rd Annual Meeting</source><publisher-loc>Denver</publisher-loc><year>2014</year></element-citation></ref><ref id="b8-opth-12-161"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schallhorn</surname><given-names>CS</given-names></name><name><surname>Schallhorn</surname><given-names>JM</given-names></name><name><surname>Hannan</surname><given-names>S</given-names></name><name><surname>Schallhorn</surname><given-names>SC</given-names></name></person-group><article-title>Effectiveness of an eyelid thermal pulsation procedure to treat recalcitrant dry eye symptoms after laser vision correction</article-title><source>J Refract Surg</source><year>2017</year><volume>33</volume><issue>1</issue><fpage>30</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">28068444</pub-id></element-citation></ref><ref id="b9-opth-12-161"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greiner</surname><given-names>JV</given-names></name></person-group><article-title>Long-term (3 year) effects of a single thermal pulsation system treatment on meibomian gland function and dry eye symptoms</article-title><source>Eye Contact Lens</source><year>2016</year><volume>42</volume><issue>2</issue><fpage>99</fpage><lpage>107</lpage><pub-id pub-id-type="pmid">26222095</pub-id></element-citation></ref><ref id="b10-opth-12-161"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qiao</surname><given-names>J</given-names></name><name><surname>Yan</surname><given-names>X</given-names></name></person-group><article-title>Emerging treatment options for meibomian gland dysfunction</article-title><source>Clin Ophthalmol</source><year>2013</year><volume>7</volume><fpage>1797</fpage><lpage>1803</lpage><pub-id pub-id-type="pmid">24043929</pub-id></element-citation></ref><ref id="b11-opth-12-161"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pflugfelder</surname><given-names>SC</given-names></name><name><surname>Geerling</surname><given-names>G</given-names></name><name><surname>Kinoshita</surname><given-names>S</given-names></name><etal></etal></person-group><article-title>Management and therapy of dry eye disease: report of the Management and Therapy Subcommittee of the International Dry Eye WorkShop (2007)</article-title><source>Ocul Surf</source><year>2007</year><volume>5</volume><issue>2</issue><fpage>163</fpage><lpage>178</lpage><pub-id pub-id-type="pmid">17508120</pub-id></element-citation></ref><ref id="b12-opth-12-161"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foulks</surname><given-names>GN</given-names></name><name><surname>Borchman</surname><given-names>D</given-names></name><name><surname>Yappert</surname><given-names>M</given-names></name><name><surname>Kakar</surname><given-names>S</given-names></name></person-group><article-title>Topical azithromycin and oral doxycycline therapy of meibomian gland dysfunction: a comparative clinical and spectroscopic pilot study</article-title><source>Cornea</source><year>2013</year><volume>32</volume><issue>1</issue><fpage>44</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">22668581</pub-id></element-citation></ref><ref id="b13-opth-12-161"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iovieno</surname><given-names>A</given-names></name><name><surname>Lambiase</surname><given-names>A</given-names></name><name><surname>Micera</surname><given-names>A</given-names></name><name><surname>Stampachiacchiere</surname><given-names>B</given-names></name><name><surname>Sgrulletta</surname><given-names>R</given-names></name><name><surname>Bonini</surname><given-names>S</given-names></name></person-group><article-title>In vivo characterization of doxycycline effects on tear metalloproteinases in patients with chronic blepharitis</article-title><source>Eur J Ophthalmol</source><year>2009</year><volume>19</volume><issue>5</issue><fpage>708</fpage><lpage>716</lpage><pub-id pub-id-type="pmid">19787586</pub-id></element-citation></ref><ref id="b14-opth-12-161"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kashkouli</surname><given-names>MB</given-names></name><name><surname>Fazel</surname><given-names>AJ</given-names></name><name><surname>Kiavash</surname><given-names>V</given-names></name><name><surname>Nojomi</surname><given-names>M</given-names></name><name><surname>Ghiasian</surname><given-names>L</given-names></name></person-group><article-title>Oral azithromycin versus doxycycline in meibomian gland dysfunction: a randomised double-masked open-label clinical trial</article-title><source>Br J Ophthalmol</source><year>2015</year><volume>99</volume><issue>2</issue><fpage>199</fpage><lpage>204</lpage><pub-id pub-id-type="pmid">25138765</pub-id></element-citation></ref><ref id="b15-opth-12-161"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoo</surname><given-names>SE</given-names></name><name><surname>Lee</surname><given-names>DC</given-names></name><name><surname>Chang</surname><given-names>MH</given-names></name></person-group><article-title>The effect of low-dose doxycycline therapy in chronic meibomian gland dysfunction</article-title><source>Korean J Ophthalmol</source><year>2005</year><volume>19</volume><issue>4</issue><fpage>258</fpage><lpage>263</lpage><pub-id pub-id-type="pmid">16491814</pub-id></element-citation></ref><ref id="b16-opth-12-161"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zandian</surname><given-names>M</given-names></name><name><surname>Rahimian</surname><given-names>N</given-names></name><name><surname>Soheilifar</surname><given-names>S</given-names></name></person-group><article-title>Comparison of therapeutic effects of topical azithromycin solution and systemic doxycycline on posterior blepharitis</article-title><source>Int J Ophthalmol</source><year>2016</year><volume>9</volume><issue>7</issue><fpage>1016</fpage><lpage>1019</lpage><pub-id pub-id-type="pmid">27500111</pub-id></element-citation></ref><ref id="b17-opth-12-161"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ngo</surname><given-names>W</given-names></name><name><surname>Situ</surname><given-names>P</given-names></name><name><surname>Keir</surname><given-names>N</given-names></name><name><surname>Korb</surname><given-names>D</given-names></name><name><surname>Blackie</surname><given-names>C</given-names></name><name><surname>Simpson</surname><given-names>T</given-names></name></person-group><article-title>Psychometric properties and validation of the Standard Patient Evaluation of Eye Dryness questionnaire</article-title><source>Cornea</source><year>2013</year><volume>32</volume><issue>9</issue><fpage>1204</fpage><lpage>1210</lpage><pub-id pub-id-type="pmid">23846405</pub-id></element-citation></ref><ref id="b18-opth-12-161"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Korb</surname><given-names>DR</given-names></name><name><surname>Blackie</surname><given-names>CA</given-names></name></person-group><article-title>Meibomian gland diagnostic expressibility: correlation with dry eye symptoms and gland location</article-title><source>Cornea</source><year>2008</year><volume>27</volume><issue>10</issue><fpage>1142</fpage><lpage>1147</lpage><pub-id pub-id-type="pmid">19034129</pub-id></element-citation></ref><ref id="b19-opth-12-161"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Finis</surname><given-names>D</given-names></name><name><surname>Konig</surname><given-names>C</given-names></name><name><surname>Hayajneh</surname><given-names>J</given-names></name><name><surname>Borrelli</surname><given-names>M</given-names></name><name><surname>Schrader</surname><given-names>S</given-names></name><name><surname>Geerling</surname><given-names>G</given-names></name></person-group><article-title>Six-month effects of a thermodynamic treatment for MGD and implications of meibomian gland atrophy</article-title><source>Cornea</source><year>2014</year><volume>33</volume><issue>12</issue><fpage>1265</fpage><lpage>1270</lpage><pub-id pub-id-type="pmid">25321941</pub-id></element-citation></ref><ref id="b20-opth-12-161"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Korb</surname><given-names>DR</given-names></name><name><surname>Greiner</surname><given-names>JV</given-names></name><name><surname>Herman</surname><given-names>J</given-names></name></person-group><article-title>Comparison of fluorescein break-up time measurement reproducibility using standard fluorescein strips versus the Dry Eye Test (DET) method</article-title><source>Cornea</source><year>2001</year><volume>20</volume><issue>8</issue><fpage>811</fpage><lpage>815</lpage><pub-id pub-id-type="pmid">11685057</pub-id></element-citation></ref><ref id="b21-opth-12-161"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lemp</surname><given-names>MA</given-names></name></person-group><article-title>Report of the National Eye Institute/Industry workshop on Clinical Trials in Dry Eyes</article-title><source>CLAO J</source><year>1995</year><volume>21</volume><issue>4</issue><fpage>221</fpage><lpage>232</lpage><pub-id pub-id-type="pmid">8565190</pub-id></element-citation></ref><ref id="b22-opth-12-161"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Veerappan</surname><given-names>A</given-names></name><name><surname>Yeo</surname><given-names>S</given-names></name><etal></etal></person-group><article-title>Clinical Trial of Thermal Pulsation (LipiFlow) in meibomian gland dysfunction with preteatment meibography</article-title><source>Eye Contact Lens</source><year>2016</year><volume>42</volume><issue>6</issue><fpage>339</fpage><lpage>346</lpage><pub-id pub-id-type="pmid">26825281</pub-id></element-citation></ref><ref id="b23-opth-12-161"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Xie</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>Evaluation of monocular treatment for meibomian gland dysfunction with an automated thermodynamic system in elderly Chinese patients: a contralateral eye study</article-title><source>J Ophthalmol</source><year>2016</year><volume>2016</volume><fpage>9640643</fpage><pub-id pub-id-type="pmid">28116143</pub-id></element-citation></ref><ref id="b24-opth-12-161"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greiner</surname><given-names>JV</given-names></name></person-group><article-title>A single LipiFlow(R) Thermal Pulsation System treatment improves meibomian gland function and reduces dry eye symptoms for 9 months</article-title><source>Curr Eye Res</source><year>2012</year><volume>37</volume><issue>4</issue><fpage>272</fpage><lpage>278</lpage><pub-id pub-id-type="pmid">22324772</pub-id></element-citation></ref><ref id="b25-opth-12-161"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Finis</surname><given-names>D</given-names></name><name><surname>Hayajneh</surname><given-names>J</given-names></name><name><surname>Konig</surname><given-names>C</given-names></name><name><surname>Borrelli</surname><given-names>M</given-names></name><name><surname>Schrader</surname><given-names>S</given-names></name><name><surname>Geerling</surname><given-names>G</given-names></name></person-group><article-title>Evaluation of an automated thermodynamic treatment (LipiFlow(R)) system for meibomian gland dysfunction: a prospective, randomized, observer-masked trial</article-title><source>Ocul Surf</source><year>2014</year><volume>12</volume><issue>2</issue><fpage>146</fpage><lpage>154</lpage><pub-id pub-id-type="pmid">24725326</pub-id></element-citation></ref><ref id="b26-opth-12-161"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Souchier</surname><given-names>M</given-names></name><name><surname>Joffre</surname><given-names>C</given-names></name><name><surname>Gregoire</surname><given-names>S</given-names></name><etal></etal></person-group><article-title>Changes in meibomian fatty acids and clinical signs in patients with meibomian gland dysfunction after minocycline treatment</article-title><source>Br J Ophthalmol</source><year>2008</year><volume>92</volume><issue>6</issue><fpage>819</fpage><lpage>822</lpage><pub-id pub-id-type="pmid">18511542</pub-id></element-citation></ref><ref id="b27-opth-12-161"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joffre</surname><given-names>C</given-names></name><name><surname>Souchier</surname><given-names>M</given-names></name><name><surname>Gregoire</surname><given-names>S</given-names></name><etal></etal></person-group><article-title>Differences in meibomian fatty acid composition in patients with meibomian gland dysfunction and aqueous-deficient dry eye</article-title><source>Br J Ophthalmol</source><year>2008</year><volume>92</volume><issue>1</issue><fpage>116</fpage><lpage>119</lpage><pub-id pub-id-type="pmid">18156378</pub-id></element-citation></ref><ref id="b28-opth-12-161"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lindsley</surname><given-names>K</given-names></name><name><surname>Matsumura</surname><given-names>S</given-names></name><name><surname>Hatef</surname><given-names>E</given-names></name><name><surname>Akpek</surname><given-names>EK</given-names></name></person-group><article-title>Interventions for chronic blepharitis</article-title><source>Cochrane Database Syst Rev</source><year>2012</year><volume>5</volume><fpage>CD005556</fpage></element-citation></ref><ref id="b29-opth-12-161"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biller</surname><given-names>JA</given-names></name><name><surname>Flores</surname><given-names>A</given-names></name><name><surname>Buie</surname><given-names>T</given-names></name><name><surname>Mazor</surname><given-names>S</given-names></name><name><surname>Katz</surname><given-names>AJ</given-names></name></person-group><article-title>Tetracycline-induced esophagitis in adolescent patients</article-title><source>J Pediatr</source><year>1992</year><volume>120</volume><issue>1</issue><fpage>144</fpage><lpage>145</lpage><pub-id pub-id-type="pmid">1731012</pub-id></element-citation></ref><ref id="b30-opth-12-161"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carroll</surname><given-names>LA</given-names></name><name><surname>Laumann</surname><given-names>AE</given-names></name></person-group><article-title>Doxycycline-induced photo-onycholysis</article-title><source>J Drugs Dermatol</source><year>2003</year><volume>2</volume><issue>6</issue><fpage>662</fpage><lpage>663</lpage><pub-id pub-id-type="pmid">14711147</pub-id></element-citation></ref><ref id="b31-opth-12-161"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Layton</surname><given-names>AM</given-names></name><name><surname>Cunliffe</surname><given-names>WJ</given-names></name></person-group><article-title>Phototoxic eruptions due to doxycycline – a dose-related phenomenon</article-title><source>Clin Exp Dermatol</source><year>1993</year><volume>18</volume><issue>5</issue><fpage>425</fpage><lpage>427</lpage><pub-id pub-id-type="pmid">8252763</pub-id></element-citation></ref><ref id="b32-opth-12-161"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Segelnick</surname><given-names>SL</given-names></name><name><surname>Weinberg</surname><given-names>MA</given-names></name></person-group><article-title>Recognizing doxycycline-induced esophageal ulcers in dental practice: a case report and review</article-title><source>J Am Dent Assoc</source><year>2008</year><volume>139</volume><issue>5</issue><fpage>581</fpage><lpage>585</lpage><pub-id pub-id-type="pmid">18451374</pub-id></element-citation></ref><ref id="b33-opth-12-161"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shapiro</surname><given-names>LE</given-names></name><name><surname>Knowles</surname><given-names>SR</given-names></name><name><surname>Shear</surname><given-names>NH</given-names></name></person-group><article-title>Comparative safety of tetracycline, minocycline, and doxycycline</article-title><source>Arch Dermatol</source><year>1997</year><volume>133</volume><issue>10</issue><fpage>1224</fpage><lpage>1230</lpage><pub-id pub-id-type="pmid">9382560</pub-id></element-citation></ref><ref id="b34-opth-12-161"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sloan</surname><given-names>B</given-names></name><name><surname>Scheinfeld</surname><given-names>N</given-names></name></person-group><article-title>The use and safety of doxycycline hyclate and other second-generation tetracyclines</article-title><source>Expert Opin Drug Saf</source><year>2008</year><volume>7</volume><issue>5</issue><fpage>571</fpage><lpage>577</lpage><pub-id pub-id-type="pmid">18759709</pub-id></element-citation></ref><ref id="b35-opth-12-161"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valentin</surname><given-names>S</given-names></name><name><surname>Morales</surname><given-names>A</given-names></name><name><surname>Sanchez</surname><given-names>JL</given-names></name><name><surname>Rivera</surname><given-names>A</given-names></name></person-group><article-title>Safety and efficacy of doxycycline in the treatment of rosacea</article-title><source>Clin Cosmet Investig Dermatol</source><year>2009</year><volume>2</volume><fpage>129</fpage><lpage>140</lpage></element-citation></ref></ref-list></back><floats-group><fig id="f1-opth-12-161" position="float"><label>Figure 1</label><caption><p>The mean SPEED scores at baseline and 3 months post treatment for the doxycycline and LipiFlow groups.</p><p><bold>Notes:</bold> After 3 months, SPEED scores were significantly improved from their baseline values in both the groups (<italic>p</italic>&lt;0.005). The mean SPEED scores of the LipiFlow group were significantly better than the doxycycline group at 3 months (<italic>p</italic>=0.030; error bars represent SD).</p><p><bold>Abbreviation:</bold> SPEED, Standard Patient Evaluation for Eye Dryness.</p></caption><graphic xlink:href="opth-12-161Fig1"></graphic></fig><fig id="f2-opth-12-161" position="float"><label>Figure 2</label><caption><p>The mean MGYLS scores at baseline and 3 months post treatment for the doxycycline and LipiFlow groups.</p><p><bold>Notes:</bold> At 3 months post treatment, both the groups demonstrated significant improvement in MGYLS scores from their baseline values (<italic>p</italic>&lt;0.005). No statistically significant difference in the mean MGYLS scores was observed between the two study groups at 3 months (<italic>p</italic>=0.096; error bars represent SD).</p><p><bold>Abbreviation:</bold> MGYLS, meibomian glands yielding liquid secretion.</p></caption><graphic xlink:href="opth-12-161Fig2"></graphic></fig><fig id="f3-opth-12-161" position="float"><label>Figure 3</label><caption><p>The mean TBUT at baseline and 3 months post treatment for the doxycycline and LipiFlow groups.</p><p><bold>Notes:</bold> Compared to the baseline, TBUT was significantly improved in the VTP group at 3 months post treatment (<italic>p</italic>=0.001); however, the improvement was not statistically significant in the doxycycline group (<italic>p</italic>=0.262). There was no significant difference in the mean TBUT values of the two groups at 3 months (<italic>p</italic>=0.155; error bars represent SD).</p><p><bold>Abbreviations:</bold> TBUT, tear breakup time; VTP, vectored thermal pulsation.</p></caption><graphic xlink:href="opth-12-161Fig3"></graphic></fig><table-wrap id="t1-opth-12-161" position="float"><label>Table 1</label><caption><p>Baseline data of the two treatment groups</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Variables</th><th valign="top" align="left" rowspan="1" colspan="1">N (eyes)</th><th valign="top" align="left" rowspan="1" colspan="1">Doxycycline group<break></break>(mean ± SD)</th><th valign="top" align="left" rowspan="1" colspan="1">N (eyes)</th><th valign="top" align="left" rowspan="1" colspan="1">LipiFlow group<break></break>(mean ± SD)</th><th valign="top" align="left" rowspan="1" colspan="1"><italic>p</italic>-value</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Age (years)</td><td valign="top" align="left" rowspan="1" colspan="1">12<xref ref-type="table-fn" rid="tfn1-opth-12-161">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">50.4±14.4</td><td valign="top" align="left" rowspan="1" colspan="1">13<xref ref-type="table-fn" rid="tfn1-opth-12-161">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">51.7±15.6</td><td valign="top" align="left" rowspan="1" colspan="1">0.841</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">LLT (µm)</td><td valign="top" align="left" rowspan="1" colspan="1">24</td><td valign="top" align="left" rowspan="1" colspan="1">67.58±21.85</td><td valign="top" align="left" rowspan="1" colspan="1">26</td><td valign="top" align="left" rowspan="1" colspan="1">73.19±18.42</td><td valign="top" align="left" rowspan="1" colspan="1">0.330</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">MGYLS</td><td valign="top" align="left" rowspan="1" colspan="1">24</td><td valign="top" align="left" rowspan="1" colspan="1">4.63±1.41</td><td valign="top" align="left" rowspan="1" colspan="1">26</td><td valign="top" align="left" rowspan="1" colspan="1">4.00±1.47</td><td valign="top" align="left" rowspan="1" colspan="1">0.133</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TBUT (seconds)</td><td valign="top" align="left" rowspan="1" colspan="1">24</td><td valign="top" align="left" rowspan="1" colspan="1">6.90±2.56</td><td valign="top" align="left" rowspan="1" colspan="1">26</td><td valign="top" align="left" rowspan="1" colspan="1">6.26±2.01</td><td valign="top" align="left" rowspan="1" colspan="1">0.329</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">SPEED score</td><td valign="top" align="left" rowspan="1" colspan="1">12<xref ref-type="table-fn" rid="tfn1-opth-12-161">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">13.42±4.17</td><td valign="top" align="left" rowspan="1" colspan="1">12<xref ref-type="table-fn" rid="tfn1-opth-12-161">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">11.00±3.30</td><td valign="top" align="left" rowspan="1" colspan="1">0.130</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CF staining</td><td valign="top" align="left" rowspan="1" colspan="1">24</td><td valign="top" align="left" rowspan="1" colspan="1">0.21±0.41</td><td valign="top" align="left" rowspan="1" colspan="1">26</td><td valign="top" align="left" rowspan="1" colspan="1">0.38±0.50</td><td valign="top" align="left" rowspan="1" colspan="1">0.179</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CLG staining</td><td valign="top" align="left" rowspan="1" colspan="1">24</td><td valign="top" align="left" rowspan="1" colspan="1">2.38±1.88</td><td valign="top" align="left" rowspan="1" colspan="1">26</td><td valign="top" align="left" rowspan="1" colspan="1">1.69±1.93</td><td valign="top" align="left" rowspan="1" colspan="1">0.119</td></tr></tbody></table><table-wrap-foot><fn><p><bold>Note:</bold></p></fn><fn id="tfn1-opth-12-161"><label>*</label><p>The number of patients.</p></fn><fn id="tfn2-opth-12-161"><p><bold>Abbreviations:</bold> CF, corneal fluorescein; CLG, conjunctival lissamine green; LLT, lipid layer thickness; MGYLS, meibomian glands yielding liquid secretion; SPEED, Standard Patient Evaluation for Eye Dryness; TBUT, tear breakup time.</p></fn></table-wrap-foot></table-wrap></floats-group></article>